Redcare Phamacy Unsp/Adr (SAEYY) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Redcare Pharmacy N.v..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.790 -- 00:00:05.691 Yes, thank you very much and good morning to everybody and very warm welcome from our 00:00:05.691 -- 00:00:09.772 side. Let's have a look at the agenda of today. 00:00:09.772 -- 00:00:15.193 So first of all, we would like to start with a recap, then a business update, afterwards 00:00:15.193 -- 00:00:21.734 financial updates, and then we have plenty of time for a Q&A session. 00:00:22.314 -- 00:00:25.415 So if we go to the next slide, 00:00:25.415 -- 00:00:28.248 let's start with an update on the guidance. 00:00:28.248 -- 00:00:34.350 As you know, we increased our 2026 guidance for revenue growth and profitability 00:00:34.350 -- 00:00:39.431 back in June. And I want to start by walking you through what changed 00:00:39.431 -- 00:00:41.191 and why. 00:00:41.191 -- 00:00:46.813 Total revenue growth, we moved the range up to 15 to 17% 00:00:46.813 -- 00:00:50.814 from 13 to 15% back in March. 00:00:50.814 -- 00:00:55.954 Rx in Germany, we now guide to 680 to 720 million 00:00:57.040 -- 00:00:59.862 up from more than 617 00:00:59.862 -- 00:01:04.985 million previously, mainly driven not so much by new customers but 00:01:04.985 -- 00:01:10.188 by higher baskets. Non-Rx growth now 10% to 12%, up 00:01:10.188 -- 00:01:16.011 from 8% to 10%. And adjusted EBITDA margin now 2.5% to 00:01:16.011 -- 00:01:17.492 3%, 00:01:17.492 -- 00:01:20.332 up from more than 2.5%. 00:01:20.794 -- 00:01:26.037 And the main drivers are broad-based, strong Q2 tradings across all business 00:01:26.037 -- 00:01:27.568 segments, 00:01:27.568 -- 00:01:32.591 continued RX adoption, especially on higher baskets, sustained 00:01:32.591 -- 00:01:35.672 acceleration on non-RX 00:01:35.672 -- 00:01:40.535 operating leverages, combined with continued efficiency impro...